Investors
News Releases
- May 27, 2021Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
- May 23, 2021Annovis Bio, Inc. Announces Pricing of Public Offering
- May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
- May 21, 2021Annovis Bio Announces Positive Phase 2 Data – ANVS401 Improves Cognition in Alzheimer’s Disease - Patients’ Cognition Improved 3.3 Points on ADAS-Cog11
- May 20, 2021Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
- May 20, 2021Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
- May 18, 2021Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research
- May 13, 2021Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome
- May 11, 2021Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
- May 10, 2021Annovis Bio to Ring Closing Bell at the New York Stock Exchange
- May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
- April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
- April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Media Coverage
Events & Presentations
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top